Alexza Pharma Reports European Launch of ADASUVE

Alexza Pharmaceuticals,Inc. (Nasdaq: ALXA) today announced that the company's commercial partnerGrupo Ferrer Internacional, S.A. has initiated sales of ADASUVE^® inhalationpowder, pre-dispensed (Staccato^® Loxapine) in the European Union ("EU"). ADASUVE is now available in Germany.  The first sale and shipment of productby Ferrer triggers a $1.25 million milestone payment to Alexza, pursuant tothe Company's collaboration agreement with Ferrer."This launch represents the first commercial sale of ADASUVE in the world, andmarks the culmination of many years of dedicated effort and rigorous clinicaldevelopment.  I am incredibly proud of the efforts by the Alexza team and ourpartner Ferrer in bringing ADASUVE to physicians in the EU for use in theirtreatment of agitated patients with schizophrenia or bipolar disorder," saidThomas B. King, President and CEO of Alexza.  "The initial launch of ADASUVEin Germany, followed by Ferrer's planned commercial roll out across the EU, isa key milestone for Alexza."Alexza received marketing authorization for ADASUVE from the EuropeanCommission in February 2013.  ADASUVE is the first inhalation therapy for therapid control of mild-to-moderate agitation in adult patients withschizophrenia or bipolar disorder authorized to be placed on the market in theEU.  The marketing authorization for ADASUVE requires that patients receiveregular treatment immediately after administration of the product to controlacute agitation symptoms.  It also requires that ADASUVE be administered onlyin a hospital setting under the supervision of a healthcare professional. Short-acting beta-agonist bronchodilator treatment should also be availablefor treatment of possible severe respiratory side-effects, such asbronchospasm."Alexza and Ferrer's effective cooperation has enabled a product launch ofADASUVE in an admirably short time following the EU approval in February2013," said Antoni Villaro, Chief Operating Officer of Ferrer.  "ADASUVE is animportant strategic product for Ferrer and we are excited to be introducingADASUVE to the EU psychiatric and hospital treatment community."Under the terms of the collaboration agreement between Alexza and Ferrer,which was announced in October 2011, Alexza is the exclusive supplier ofADASUVE, responsible for all aspects of manufacture of the product.  Alexzabegan manufacturing launch quantities of the product for the EU in the secondquarter of 2013 at its Mountain View, California facility.  The commercialproduct was shipped to Ferrer in June 2013, and Ferrer completed EU productquality control release and final packaging in preparation for the plannedthird quarter launch.  Ferrer is expected to launch ADASUVE in additional EUcountries before year-end and will continue the EU launch into 2014. Alexza and Ferrer estimate that as many as 8 million adults in the EU alonesuffer from schizophrenia or bipolar disorder^1.  Agitation is a commonsymptom for these patients^2, characterized by feelings of distress, anxietyand loss of control.